NCT00725439View on ClinicalTrials.gov

An Open Label Trial to Assess the Safety and Efficacy of Oral R115866 in the Treatment Facial Acne

PHASE2CompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

September 30, 2004

Primary Completion Date

July 31, 2005

Study Completion Date

December 31, 2007

Conditions
Acne
Interventions
DRUG

Talarozole

Oral Dose 1.0 mg once daily

Trial Locations (3)

B-1090

Department of Dermatology, UZ Brussel, Brussels

B-1800

Private Practice in Dermatology, Vilvoorde

NL-3331 LZ

Albert Schweitzer Hospital, Dermatology, Zwijndrecht

All Listed Sponsors
lead

Stiefel, a GSK Company

INDUSTRY

NCT00725439 - An Open Label Trial to Assess the Safety and Efficacy of Oral R115866 in the Treatment Facial Acne | Biotech Hunter | Biotech Hunter